NASDAQ:CDT

CDT Equity Q4 2025 Earnings Results & Report

CDT Equity logo
$0.34 -0.03 (-8.49%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CDT Equity reported Q4 2025 earnings on April 15, 2026. The company reported EPS of $3,475,550.00.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

CDT Equity EPS Results

Actual EPS
$3,475,550.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CDT Equity Q4 2025 Earnings FAQ

CDT Equity (NASDAQ:CDT) reported earnings of $3,475,550.00 per share for Q4 2025. The report was announced on Wednesday, April 15, 2026.

CDT Equity Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
CDT Equity Announces 1-for-20 Reverse Stock Split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

CDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs.

Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch.

Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.

View CDT Equity Profile